Navamedic Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 1/6
Navamedic has been growing earnings at an average annual rate of 49.8%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 23.5% per year. Navamedic's return on equity is 1.7%, and it has net margins of 0.7%.
Key information
49.8%
Earnings growth rate
49.8%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | 23.5% |
Return on equity | 1.7% |
Net Margin | 0.7% |
Next Earnings Update | 16 Aug 2024 |
Recent past performance updates
Recent updates
Is Navamedic (OB:NAVA) Using Too Much Debt?
Sep 19Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly
Feb 18Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality
Nov 09Is Navamedic (OB:NAVA) A Risky Investment?
Nov 02Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden
Feb 22We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt
Sep 04Is Navamedic (OB:NAVA) Using Too Much Debt?
Apr 12If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today
Feb 18Is Navamedic (OB:NAVA) Using Debt Sensibly?
Dec 07Revenue & Expenses BreakdownBeta
How Navamedic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 512 | 4 | 147 | 0 |
30 Sep 23 | 503 | 24 | 80 | 0 |
30 Jun 23 | 454 | 20 | 56 | 0 |
31 Mar 23 | 441 | 43 | 57 | 0 |
31 Dec 22 | 382 | 29 | 48 | 0 |
30 Sep 22 | 356 | 12 | 59 | 0 |
30 Jun 22 | 327 | 8 | 47 | 0 |
31 Mar 22 | 283 | 4 | 49 | 0 |
31 Dec 21 | 278 | 1 | 44 | 0 |
30 Sep 21 | 244 | -7 | 50 | 0 |
30 Jun 21 | 237 | -6 | 38 | 0 |
31 Mar 21 | 213 | -8 | 46 | 0 |
31 Dec 20 | 210 | -16 | 33 | 0 |
30 Sep 20 | 202 | -22 | 58 | 0 |
30 Jun 20 | 194 | -24 | 33 | 0 |
31 Mar 20 | 199 | -26 | 34 | 0 |
31 Dec 19 | 189 | -16 | 33 | 0 |
30 Sep 19 | 193 | -1 | 32 | 0 |
30 Jun 19 | 189 | 0 | 27 | 0 |
31 Mar 19 | 187 | 10 | 25 | 0 |
31 Dec 18 | 184 | 4 | 26 | 0 |
30 Sep 18 | 177 | -20 | 30 | 0 |
30 Jun 18 | 178 | -13 | 28 | 0 |
31 Mar 18 | 222 | -20 | 30 | 0 |
31 Dec 17 | 258 | -16 | 30 | 0 |
30 Sep 17 | 294 | 3 | 31 | 0 |
30 Jun 17 | 315 | 4 | 32 | 0 |
31 Mar 17 | 292 | -9 | 31 | 0 |
31 Dec 16 | 274 | -11 | 31 | 0 |
30 Sep 16 | 258 | -28 | 31 | 0 |
30 Jun 16 | 254 | -30 | 30 | 0 |
31 Mar 16 | 247 | -17 | 28 | 0 |
31 Dec 15 | 248 | -11 | 26 | 0 |
30 Sep 15 | 245 | -4 | 23 | 0 |
30 Jun 15 | 242 | 1 | 21 | 0 |
31 Mar 15 | 242 | 1 | 20 | 0 |
31 Dec 14 | 223 | -1 | 19 | 0 |
30 Sep 14 | 204 | 1 | 19 | 0 |
30 Jun 14 | 182 | -2 | 19 | 0 |
31 Mar 14 | 161 | -3 | 20 | 0 |
31 Dec 13 | 152 | -1 | 20 | 0 |
30 Sep 13 | 134 | 0 | 20 | 0 |
30 Jun 13 | 118 | -1 | 20 | 0 |
Quality Earnings: NAVA has a large one-off loss of NOK16.1M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: NAVA's current net profit margins (0.7%) are lower than last year (7.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NAVA has become profitable over the past 5 years, growing earnings by 49.8% per year.
Accelerating Growth: NAVA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NAVA had negative earnings growth (-87%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).
Return on Equity
High ROE: NAVA's Return on Equity (1.7%) is considered low.